Pharmaceutical major Zydus Lifesciences has finalized an agreement to construct a new $20 million manufacturing facility in Sri Lanka. The multi-million-dollar deal marks a key expansion of the company’s regional operational footprint, with the facility scheduled for completion by 2028.
The strategic project aims to bolster healthcare production capacity and strengthen regional drug supply chains. Under the agreed terms, the $20 million investment will fund the development of the pharmaceutical plant from the ground up, establishing local manufacturing infrastructure over the four-year development timeline.
Key Developments
- Investment Commitment: A $20 million agreement signed for drug manufacturing infrastructure in Sri Lanka.
- Project Timeline: The pharmaceutical facility is scheduled to be completed and operational by 2028.
- Regional Expansion: Strengthens Zydus Lifesciences’ presence and manufacturing capability in South Asia.
The investment underscores a growing focus on building localized pharmaceutical manufacturing capabilities across South Asia. Securing specialized foreign investment through 2028 offers Sri Lanka an opportunity to enhance domestic drug supply security while reducing reliance on imported finished pharmaceuticals.